Lilly osteoporosis agent raloxifene lowers total cholesterol 7%, similar to estrogen.
Executive Summary
LILLY RALOXIFENE LOWERS TOTAL CHOLESTEROL BY 7%, a rate comparable to estrogen therapy, according to data from a comparative study of lipid effects of raloxifene and estrogens presented at the National Osteoporosis Foundation International Symposium in Washington, D.C. June 5. Lilly is pursuing marketing of raloxifene as an alternative to estrogen therapy to prevent osteoporosis.